- Drug discovery services
- Our technology
- Your benefits
- Resources & Webinars
- News & Events
- About us
Jan 1 2021
For BioTheryX, Inc., a clinical-stage biopharmaceutical company focused on restoring protein homeostasis
through protein modulation, 2020 has been a fruitful year!
The company launched a Phase 1 Clinical Trial of BTX-A51 in January and announced a $35 Million
Series D financing in July.
We are proud to contribute to BioTheryX, Inc. preclinical efforts!